L-nucleosides as ligands to adenosine receptors

Details L-nucleosides as ligands to adenosine receptors L-nucleosides as ligands to adenosine receptors

2006-09-08

2008-09-09

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027220

Reexamination Certificate

active

07423025

ABSTRACT:
Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed compounds to treat cardiovascular disease, ischemia related injuries; and neurodegenerative diseases. The compounds disclosed herein have the formula:wherein R1and R2are, independently, H, branched or straight-chain, substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl; R3is branched or straight-chain, substituted or unsubstituted alkyl, hydroxy-alkyl, or —C(═O)NR6R7; and R4and R5are, independently, H, hydroxy, halogen, and NR8R9,wherein R6, R7, R8, and R9are, independently, H, branched or straight-chain, substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl.

REFERENCES:
Al Safarjalani et al., “Uptake of nitrobenzylthioinosine and purine β-L-nucleosides by intracellularToxoplasma gondii,” Antimicrob. Agents Chemother. 2003, 47, 3247-3251.
Angulo et al., “A1Adenosine receptors accumulate in neurodegenerative structures in Alzheimer's disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation,”Brain Pathol. 2003, 13, 440-451.
Baker et al., “Synthetic studies. VIII. Synthesis of 3-amino-3-deoxy-D-ribofuranoside derivatives. A second synthesis of 3-amino-3-deoxy-D-ribose,”J. Am. Chem. Soc. 1955, 77, 7-12.
Baker et al., “Synthetic studies. IX. Total synthesis,”J. Am. Chem. Soc. 1955, 77, 12-15.
Behan and Stone, “Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2areceptor antagonists,”Brit. J. Pharmacol. 2002, 135, 1435-1442.
Blum et al., “The adenosine A1receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicitym,”J. Neurosci. 2002, 22, 9122-9133.
Brown et al., “Evidence for stereospecificity of the P1-purinoceptor,”Br. J. Pharmacol. 1982, 75, 101-107.
Burnstock et al., “Evidence that the P1-purinoceptor in the guinea-pigtaenia coliis an A2-subtype,”Br. J. Pharmacol.1984, 81, 533-541.
Canyon and Dobson, “Pretreatment with an adenosine A1 receptor agonist and lidocaine: A possible alternative to myocardial ischemic preconditioning,”J. Thorac. Cardiovasc. Surg.2005, 130, 371-377.
Carter et al., “Isolation and functional characterization of the PfNT1 nucleoside transporter gene fromPlasmodium falciparum,”J. Biol. Chem. 2000, 275, 10683-10691.
Chase et al., “Translating A2aantagonist KW6002 from animal models to parkinsonian patients,”Neurology2003, 61, S107-S111.
Chen et al., “Neuroprotection by caffeine and A2Aadenosine receptor inactivation in a model of Parkinson's disease,”J. Neurosci. 2001, 21, 143-148.
Cusack et al., “Effects of D- and L-enantiomers of adenosine, AMP and ADP and their 2-chloro- and 2-azido- analogues on human platelets,”Proc. R. Soc. Lond. B Bio. Sci.1979, 206, 139-144.
Cusack and Planker, “Relaxation of isolatedtaenia coliof guinea-pig by enantiomers of 2-azido analogues of adenosine and adenine nucleotides,”Br. J. Pharmacol.1979, 67, 153-158.
Dall'Igna et al., “Neuroprotection by caffeine and adenosine A2Areceptor blockade of β-amyloid neurotoxicity,”Brit. J. Pharmacol. 2003, 138, 1207-1209.
Dall'Igna et al., “Caffeine as a neuroprotective adenosine receptor antagonist,”Ann. Pharmacother.2004, 38, 717-718.
De Giovanni et al., “Adenosine induced transient cardiac standstill in catheter interventional procedures for congenital heart disease,”Heart1998, 80, 330-333.
de Jong et al., “The role of adenosine in preconditioning,”Pharmacol. Ther. 2000, 87, 141-149.
de Jonge et al., “Role of adenosine and glycogen in ischemic preconditioning of rat hearts,”Eur. J. Pharmacol. 2001, 414, 55-62.
DeNinno et al., “3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3receptor,”J. Med. Chem.2003, 46, 353-355.
Donato and Gelpi, “Adenosine and cardioprotection during reperfusion—an overview,”Mol. Cell. Biochem. 2003, 251, 153-159.
Fishman et al., “The A3 adenosine receptor as a new target for cancer therapy and chemoprotection,”Exp. Cell Res. 2001, 269, 230-236.
Fishman et al., “A3 adenosine receptor as a target for cancer therapy,”Anticancer Drugs2002, 13, 437-443.
Fredholm et al., “International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors,”Pharmacol. Rev.2001, 53, 527-552.
Gilbert et al., “Synthesis of L,L-puromycin,”Tetrahedron2005, 61, 8339-8344.
Glover et al., “Reduction of infarct size and post-ischemic inflammation from ATL-146e, a highly selective adenosine A2areceptor agonist, in reperfused canine myocardium,”Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H1851-H1858.
Gumina et al., “L-Nucleosides as chemotherapeutic agents,”FEMS Microbiol. Lett. 2001, 202, 9-15.
Gumina et al., “L-Nucleosides: Antiviral activity and molecular mechanism,”Curr. Top. Med. Chem.2002, 2, 1065-1086.
Hafner, “Cytosensor® Microphysiometer: technology and recent applications,”Biosens. Bioelectron. 2000, 15, 149-158.
Hein et al., “Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine,”J. Mol. Cell. Cardiol. 2001, 33, 271-282.
Jordan et al., “Adenosine A2receptor activation attenuates reperfusion injury by inhibiting neutrophils accumulation, superoxide generation, and coronary endothelial adherence,”J. Pharmacol. Exp. Ther. 1997, 280, 301-309.
Jurovcik et al., “The utilization of L-adenosine by mammalian tissues,”FEBS Lett. 1971, 18, 274-276.
McConnell et al., “The cytosensor microphysiometer: biological applications of silicon technology,”Science1992, 257, 1906-1907.
Müller, “Medicinal chemistry of adenosine A3receptor ligands,”Curr. Top. Med. Chem. 2003, 3, 445-462.
Mustafa and Askar, “Evidence suggesting an Ra-type adenosine receptor in bovine coronary arteries,”J. Pharmacol. Exp. Ther. 1985, 232, 49-56.
Nair and Emanuel, “Synthetic design, stereochemistry, and enzymatic activity of a reversed aminoacyl nucleoside: An analogue of puromycin,”J. Am. Chem. Soc. 1977, 99, 1571-1576.
Nussbaum et al., “Transient cardiac standstill induced by adenosine in the management of intraoperative aneurysmal rupture: Technical case report,”Neurosurgery2000, 47, 240-243.
Okada et al., “Two-phase response of acid extrusion triggered by purinoceptor in Chinese hamster ovary cells,”Eur. J. Pharmacol.2002, 455, 19-25.
Okamura et al., “Structure-activity relationships of adenosine A3receptor ligands: new potential therapy for the treatment of glaucoma,”Bioorg. Med. Chem. Lett. 2004, 14, 3775-3779.
Patel et al., “Comparison of human recombinant adenosine A2B receptor function assessed by Fluo-3-AM fluorometry and microphysiometry,”Br. J. Pharmacol. 2003, 138, 671-677.
Peart and Headrick, “Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects,”Cardiovasc. Res. 2003, 58, 589-601.
Pinna et al., “New adenosine A2Areceptor antagonists: actions on Parkinson's disease models,”Eur. J. Pharmacol. 2005, 512, 157-164.
Rabinowitz et al., “Potentiometric measurement of intracellular redox activity,”J. Am. Chem. Soc. 1998, 120, 2464-2473.
Schwarzschild et al., “Neuroprotection by caffeine and more specific A2areceptor antagonists in animal models of Parkinson's disease,”Neurology2003, 61, S55-S61.
Shryock and Belardinelli, “Ade

Affiliated with

Also associated with

Rating

L-nucleosides as ligands to adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with L-nucleosides as ligands to adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-nucleosides as ligands to adenosine receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3986553